Newton Biocapital

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.

AdipoPharma SAS is a biotechnology company focused on exploring the role of adipocyte cells in diabetes management. It develops peptide-based drugs aimed at treating insulin resistance, type 2 diabetes, and associated comorbidities. The company conducts in-depth genetic investigations, particularly related to Alström syndrome, utilizing a therapeutic approach that targets specific cellular mechanisms. By examining the complex functions of adipocytes and their effects on lipid metabolism, AdipoPharma seeks to restore healthy lipid biosynthesis in diseased adipocytes. This targeted method aims to enhance insulin sensitivity, facilitate the removal of beta-cell plaques, and reduce liver steatosis and fibrosis, ultimately providing low-risk treatment options for diabetes patients.

AbolerIS Pharma is a biotechnology company based in Nantes, France, specializing in the development of immune-modulators aimed at treating transplant rejection, graft-versus-host disease, and autoimmune diseases. Incorporated in 2019, the company offers innovative products such as Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma employs a unique therapeutic approach that fosters immune tolerance while preserving beneficial immune responses in the context of inflammatory, autoimmune, and degenerative diseases. This strategy allows the company to focus on advancing novel drugs to address significant unmet medical needs in these therapeutic areas.

Santero Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics aimed at addressing the challenge of multi-drug-resistant pathogens. The company concentrates on creating novel medications that utilize fresh modes of action to effectively combat diseases with high resistance, particularly in the realm of antibiotic-resistant microorganisms. Santero's products are designed to offer prolonged efficacy, reducing the likelihood of new resistance emerging and providing patients with better-tolerated treatment options for complex infections. Through its commitment to advancing antimicrobial therapies, Santero Therapeutics aims to improve patient outcomes in the face of rising antibiotic resistance.

AdipoPharma SAS is a biotechnology company focused on exploring the role of adipocyte cells in diabetes management. It develops peptide-based drugs aimed at treating insulin resistance, type 2 diabetes, and associated comorbidities. The company conducts in-depth genetic investigations, particularly related to Alström syndrome, utilizing a therapeutic approach that targets specific cellular mechanisms. By examining the complex functions of adipocytes and their effects on lipid metabolism, AdipoPharma seeks to restore healthy lipid biosynthesis in diseased adipocytes. This targeted method aims to enhance insulin sensitivity, facilitate the removal of beta-cell plaques, and reduce liver steatosis and fibrosis, ultimately providing low-risk treatment options for diabetes patients.

DeuterOncology is a preclinical-stage biotechnology company dedicated to advancing cancer treatment through innovative therapies. The firm is developing a first-in-class dual MET and RAS pathway inhibitor, which is currently undergoing preclinical investigation. This lead compound aims to serve as a targeted therapy primarily for lung cancer, while also holding promise for broader applications in oncology when used in combination with standard of care and other targeted agents. By focusing on optimizing treatment outcomes, DeuterOncology seeks to empower medical professionals in their efforts to effectively combat cancer.

NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as Alzheimer's. It is based on discoveries about the molecular mechanisms that keep the blood-brain barrier intact (BBB). The BBB regulates the exchange of information between the vascular and central nervous systems (CNS). Increased BBB permeability, whether due to age or injury, plays a role in many neurological conditions by allowing harmful blood substances to enter the CNS. Many neurodegenerative disorders, such as Alzheimer's, as well as a variety of acute neurological conditions, such as stroke and epilepsy, are associated with BBB dysfunction.

EditForce Inc. is a biotechnology company based in Fukuoka, Japan, founded in 2015. It specializes in developing innovative technologies for genome and RNA editing, particularly through the engineering of pentatricopeptide repeat (PPR) proteins. EditForce's advanced tools facilitate the manipulation of nucleic acids, enabling precise editing of DNA and RNA at a genomic scale. This technology is applicable across various fields, including biological research, medicine, agriculture, and bio-production, allowing for the development of drugs and genetically modified seeds. By providing alternative genome editing solutions, EditForce aims to advance scientific research and improve agricultural outcomes.

DeuterOncology is a preclinical-stage biotechnology company dedicated to advancing cancer treatment through innovative therapies. The firm is developing a first-in-class dual MET and RAS pathway inhibitor, which is currently undergoing preclinical investigation. This lead compound aims to serve as a targeted therapy primarily for lung cancer, while also holding promise for broader applications in oncology when used in combination with standard of care and other targeted agents. By focusing on optimizing treatment outcomes, DeuterOncology seeks to empower medical professionals in their efforts to effectively combat cancer.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery. Established in 2001, it specializes in antibody discovery, engineering, and research support activities. The company engages in target discovery and functional protein expression, offering services such as mouse hybridoma sequencing, recombinant protein production, and contract research for antibodies. Additionally, Perseus Proteomics develops, manufactures, and supplies a range of antibody products. By leveraging advanced antibody technology, the company aims to create innovative medicines that address the needs of patients worldwide seeking improved medical care.

AbolerIS Pharma is a biotechnology company based in Nantes, France, specializing in the development of immune-modulators aimed at treating transplant rejection, graft-versus-host disease, and autoimmune diseases. Incorporated in 2019, the company offers innovative products such as Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma employs a unique therapeutic approach that fosters immune tolerance while preserving beneficial immune responses in the context of inflammatory, autoimmune, and degenerative diseases. This strategy allows the company to focus on advancing novel drugs to address significant unmet medical needs in these therapeutic areas.

J-Pharma is a pharmaceutical company dedicated to improving human health by developing novel drugs based on a human-genomic approach. The company focuses on creating selective agents to treat specific diseases, with an emphasis on cell membrane transporters closely associated with various illnesses. J-Pharma's intellectual property includes the discovery of important drug transporters within the human body, which can be used to evaluate and optimize the pharmacokinetics of new drug candidates. Their pipeline aims to produce new therapeutic agents and diagnostic methods, particularly targeting cancer treatment through drugs like anti-cancer agents and PET diagnostic agents against LAT1. The company's ultimate goal is to enhance the quality of life for an aging population in industrialized countries and contribute globally to human welfare.

EditForce Inc. is a biotechnology company based in Fukuoka, Japan, founded in 2015. It specializes in developing innovative technologies for genome and RNA editing, particularly through the engineering of pentatricopeptide repeat (PPR) proteins. EditForce's advanced tools facilitate the manipulation of nucleic acids, enabling precise editing of DNA and RNA at a genomic scale. This technology is applicable across various fields, including biological research, medicine, agriculture, and bio-production, allowing for the development of drugs and genetically modified seeds. By providing alternative genome editing solutions, EditForce aims to advance scientific research and improve agricultural outcomes.

Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.

Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

ChromaCure is a biotechnology company focused on developing innovative cancer therapies. The company specializes in discovering first-in-class small molecule therapeutics that address unmet needs in oncology. ChromaCure's primary goal is to identify potential new drug candidates that selectively and potently inhibit cancer targets, offering novel treatment options for various forms of cancer. These therapies are designed to be used either as monotherapy or in combination with existing treatments such as immunotherapy or chemotherapy, aiming to provide more effective solutions for cancer patients.

Synergia Medical is focused on the development and commercialization of next-generation neurostimulation devices, leveraging optoelectronics technology. The company specializes in creating MRI-safe, implantable neurostimulators designed primarily for drug-resistant epilepsy, with potential applications in various therapeutic areas. By replacing traditional wires with fiber optics, Synergia's devices utilize photovoltaic cells to convert optical energy into electrical impulses, enhancing their functionality and safety. Over a brief period of three years, Synergia Medical has achieved ISO13485 certification, successfully developed and marketed an OEM external neurostimulator for motorized prosthetic arms, and launched its initial NAOS platform. Supported by private investors and public research grants, the company has expanded its team to thirteen highly skilled professionals with extensive experience in the field, underscoring its commitment to innovation in neurostimulation technology.

Dim3 SA is a Belgian company established in 2013 that focuses on developing and marketing innovative clinical expert platforms and medical devices aimed at improving clinical nutrition management. The company's product offerings include Scorso, an application designed for the screening and monitoring of disease-related malnutrition; Nutrow, a decision support software that optimizes clinical nutrition strategies; and Biocorder, a clinical mobile assistant. These solutions aim to expedite medical decisions, enhance patient outcomes, and reduce healthcare costs, particularly in addressing the significant issue of disease-related malnutrition, which poses serious health risks and incurs substantial financial burdens in Europe.